Introducing DHX9 & ATX-559 as a Novel DDR Program to Broaden Therapeutic Opportunities in Early-Phase Trials

• See how Accent Therapeutics is pioneering DHX9-targeted therapy with their lead compound ATX-559

• Outlining the Phase 1 trial dose-escalation design and key study objectives

• Sharing translational insights from preclinical data, including biomarker strategy and combination potential to guide future development

Speakers:

Jenn Castro

Director of Translational and Discovery Biology

Accent Therapeutics